Table 2 Treatment landscape

Pralsetinib alone

28(43.8%)

Pralsetinib + Antiangio

3

Pralsetinib + Bevacizumab

2

Pralsetinib + Anlotinib

1

Chemo

11(17.2%)

Carboplatin + Pemetrexed

4

Cisplatin + Pemetrexed

2

Nedaplatin + Pemetrexed

1

Pemetrexed

1

Nedaplatin + Docetaxel

1

Lobaplatin + Docetaxel

1

Gemcitabine + Carboplatin

1

Chemo + Antiangio

8(12.5%)

Cisplatin + Pemetrexed + Bevacizumab

5

Carboplatin + Pemetrexed + Bevacizumab

3

Immuo + Antiangio

1(1.6%)

Penpulimab + Anlotinib

1

Chemo + Immuno + Antiangio

3(4.7%)

Carboplatin + Pemetrexed + Bevacizumab + Pembrolizumab

2

Cisplatin + Abraxane + Bevacizumab + Sintilimab

1

MKI

10(15.6%)

Cabozantinib

6

Alectinib

2

Vandetanib

1

Sufatinib

1

Patients treated with lung surgeries, n (%)

13(20.3%)

Patients treated with radiotherapy, n (%)

10(15.6%)